Breast Cancer Research and Treatment最新文献

{"title":"Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer.","authors":"Amanda Sutherland Beck, Michelle Earley, Megan Troxell, Jacqueline Tsai, Melinda L Telli, Irene L Wapnir","doi":"10.1007/s10549-025-07722-6","DOIUrl":"https://doi.org/10.1007/s10549-025-07722-6","url":null,"abstract":"<p><strong>Purpose: </strong>Neoadjuvant chemotherapy has been used to evaluate tumor response and downstage hormone sensitive localized breast cancers. However, complete pathological responses are uncommon. Neoadjuvant endocrine therapy (NET) has been used sparingly for the treatment of hormone receptor (HR)-positive breast cancers and frequently for six months or less. There is no clear definition of response to NET nor well-defined parameters for duration of treatment.</p><p><strong>Methods: </strong>A retrospective chart review of patients with HR-positive localized invasive breast cancers treated with NET for at least 2 months was performed at a single institution. Clinical features, drug selection, duration of therapy, type of surgery as well as pathological characteristics, and residual tumor cellularity were analyzed. A multivariable linear regression model was used to examine the association between NET length and residual invasive tumor cellularity.</p><p><strong>Results: </strong>104 evaluable HR-positive invasive breast cancers were treated with NET over an 11-year period. Median age was 69 (range: 31-89) and 88% were post-menopausal. The median duration of treatment was 8 months, with 61% having at least 7 months. Patients receiving NET for 7 months or longer had a significantly lower residual cellularity (20.4%) compared to those treated 2-6 months (34.9%) (p = 0.006). Both pre-treatment and post-treatment Ki-67 ≤ 10% were associated with a lower residual invasive tumor cellularity. Residual invasive cellularity was not associated with menopausal status or NET agent.</p><p><strong>Conclusion: </strong>Longer NET duration is associated with greater tumor response. Mean residual invasive tumor cellularity was 42% lower among patients receiving 7 or more months of NET.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COVID-19 pandemic interruption of breast cancer screening is linked to clinical upstaging at presentation: the roles of demographics, socioeconomic status and unmet social needs.","authors":"Roham Hadidchi, Katie S Duong, Julia Hou, Takouhie Maldjian, Julie Chung, Wei Hou, Susan Fineberg, Jinyu Lu, Della Makower, Tim Q Duong","doi":"10.1007/s10549-025-07713-7","DOIUrl":"https://doi.org/10.1007/s10549-025-07713-7","url":null,"abstract":"<p><strong>Background: </strong>COVID-19 pandemic-related disruptions of mammography screening, breast cancer diagnosis, staging, and treatment options are not well understood with respect to social determinants of health, especially three years post-pandemic.</p><p><strong>Methods: </strong>This retrospective observational study included patients screened by mammography or diagnosed with breast cancer from January 2019 to February 2023 in the urban population in the Bronx.</p><p><strong>Results: </strong>Screening and diagnostic mammography, and breast cancer diagnoses from April to August 2020 dropped by 61%, 47%, and 42%, respectively, compared to pre-pandemic (Jan 2019-Mar 2020) and largely recovered by September 2020. Compared to pre-pandemic baseline, patients diagnosed with breast cancer from September 2020 to January 2021 were 1.48 times (95% CI [1.03, 2.13]) more likely to present with clinical stage 2-4, and 1.47 [1.04-2.08] times more likely to present with T stage 2-4. Black patients experienced a more significant increase in odds of presenting with clinical stage 2-4 (4.41 [1.36, 14.24]) and nodal involvement (4.61 [1.27, 16.82]) compared to non-Hispanic Whites from Apr 2020 to Jan 2021.</p><p><strong>Conclusion: </strong>Interruption of breast cancer screening during the pandemic coincided with increased proportions of patients presenting with more advanced disease, especially among Black patients. The results underscore the need for targeted public health interventions to address health disparities among these populations.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients.","authors":"Kirsten M Woolpert, Thomas P Ahern, James W Baurley, Maret L Maliniak, Per Damkier, Anders Kjærsgaard, Lindsay J Collin, Stephen Hamilton-Dutoit, Trine Tramm, Bent Ejlertsen, Henrik T Sørensen, Timothy L Lash, Deirdre P Cronin-Fenton","doi":"10.1007/s10549-025-07719-1","DOIUrl":"https://doi.org/10.1007/s10549-025-07719-1","url":null,"abstract":"<p><strong>Purpose: </strong>Premenopausal, estrogen receptor (ER)-positive breast cancer patients should receive tamoxifen for at least 5 years, but many prematurely discontinue. Activation, transport, and deactivation of tamoxifen and its metabolites are controlled by proteins encoded by genes with functional variations. We examined the impact of genetic polymorphisms in the tamoxifen pathway on early treatment discontinuation.</p><p><strong>Methods: </strong>We included premenopausal women diagnosed with ER-positive breast cancer (2002-2011) in Denmark who initiated tamoxifen. We genotyped 26 genetic variants in 15 enzymes involved in tamoxifen metabolism. Early discontinuation was defined as tamoxifen use for < 5 years. We estimated individual and combined effects of genetic variants using a Bayesian pathway approach. We report Bayes Factors (BF), wherein values > 1 indicate support of an effect of the genetic pathway on discontinuation (compared with no effect).</p><p><strong>Results: </strong>Among 3,729 patients, 536 (14%) discontinued tamoxifen within 5 years. Genetic variants involved in tamoxifen activation impacted early discontinuation (BF = 7.5), in a manner driven almost entirely by CYP2D6 activity (BF = 22.6). Several variants in CYP2D6 and transporter genes synergistically increased the hazard of early discontinuation (e.g., CYP2D6*2 and ABCC2; BF = 138).</p><p><strong>Conclusions: </strong>Variants in enzymes responsible for activating tamoxifen metabolites-particularly within CYP2D6-influence early tamoxifen discontinuation. CYP2D6 variants synergistically interact with transporter gene variants, namely ABCC2, to further raise the risk of discontinuation.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiation recall dermatitis induced by abemaciclib with successful rechallenge: a case series and literature review.","authors":"Zi-Lu Yi, Bei-Bei Yang, Jia-Ning Zhang, Meng-Jun Zhao, Meng-Lu Shen, Xi-Rui Zhou, Hong Liu","doi":"10.1007/s10549-025-07712-8","DOIUrl":"https://doi.org/10.1007/s10549-025-07712-8","url":null,"abstract":"<p><strong>Purpose: </strong>To raise awareness of radiation recall dermatitis (RRD) in the context of radiotherapy combined with abemaciclib, and to explore its potential mechanisms, characteristics, and treatment options.</p><p><strong>Methods: </strong>We conducted a case series study reporting the first instances of RRD induced by abemaciclib in two women with locally advanced luminal breast cancer. Both patients experienced skin reactions in previously irradiated areas following abemaciclib administration. Additionally, a comprehensive literature review was performed to analyze the potential mechanisms of RRD, characteristics of radiotherapy, triggering drugs, and available treatments.</p><p><strong>Results: </strong>The case series demonstrated that abemaciclib can induce RRD in patients who have undergone radiotherapy. Both patients experienced significant skin reactions, which were successfully managed and resolved upon rechallenge with abemaciclib. The literature review highlighted the importance of recognizing RRD as a potential adverse effect of cyclin-dependent kinase 4/6 inhibitors (CDK4/6is), emphasizing the need for careful monitoring and appropriate management strategies.</p><p><strong>Conclusion: </strong>Radiation recall dermatitis is a potential adverse effect of abemaciclib in patients receiving radiotherapy for breast cancer. Our findings underscore the importance of awareness and vigilance in managing patients on CDK4/6is.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer.","authors":"Margaux Wooster, Ling Chen, Melissa K Accordino, Claire Sathe, Jason D Wright, Dawn L Hershman","doi":"10.1007/s10549-025-07714-6","DOIUrl":"https://doi.org/10.1007/s10549-025-07714-6","url":null,"abstract":"<p><strong>Purpose: </strong>Overweight and obese breast cancer (BC) survivors face higher risks of recurrence and all-cause mortality, including from cardiovascular disease (CVD). Weight management therapy (WMT) may reduce cardiovascular events (CVE). We assessed trends in WMT in BC survivors and evaluated rates of CVE.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study using the MarketScan Database, including overweight and obese patients (18-95 years) with invasive BC (2009 -2021), who underwent breast surgery. Exclusions were prior bariatric surgery or secondary cancers. Patients were categorized by weight status and by WMT, including nutrition counseling, medications, and bariatric surgery. We utilized descriptive statistics, univariate analysis for factors associated with WMT receipt and rates of CVE, and a multivariable logistic regression model to determine WMT-associated factors.</p><p><strong>Results: </strong>We identified 35,206 patients: 18.8% overweight, 53.7% obese class I/II/unspecified, and 27.4% obese class III. WMT was utilized by 5.3%, 6.4%, and 9.6%, respectively (p < 0.001). Among 2,484 patients who received WMT, 72.7% had nutrition counseling, 26.7% received weight loss medication, and 4.9% underwent bariatric surgery. From 2009 to 2021, WMT use increased from 3.7% to 11.3% (p < 0.001), and use of weight loss medication increased from 0.3% to 5.1% (p < 0.001). Factors associated with receipt of WMT included younger age, greater degree of obesity, more recent year of surgery, lumpectomy, higher comorbidity score, and prior WMT. CVE incidence was lower in WMT recipients (0.8% vs.1.3%, p = 0.02).</p><p><strong>Conclusion: </strong>In patients with BC, WMT has increased over time, and most markedly weight loss medication use. WMT is associated with lower incidence of CVE.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen.","authors":"Stephanie L Safgren, Vera J Suman, Roberto A Leon Ferre, Matthew L Kosel, Vered Stearns, N Lynn Henry, Neelima Denduluri, William Irvin, James N Ingle, Kostantinos Sideras, Matthew M Ames, Joel M Reid, Charles L Loprinzi, John L Black, Richard M Weinshilboum, Matthew P Goetz","doi":"10.1007/s10549-025-07644-3","DOIUrl":"10.1007/s10549-025-07644-3","url":null,"abstract":"<p><strong>Purpose: </strong>Tamoxifen undergoes metabolic activation by cytochrome P450 (CYP) enzymes to metabolites with more potent anti-estrogenic effects. Numerous studies demonstrate decreased tamoxifen efficacy associated with reduced CYP2D6 activity or lower Z-endoxifen concentrations. Women taking tamoxifen frequently experience vasomotor symptoms (VMS) that may require medical treatment. Many medications used for VMS or depression are CYP substrates that may reduce Z-endoxifen concentrations. While the drug-drug interactions (DDI) from potent CYP2D6 inhibitors (CYPi) on tamoxifen metabolism has been studied, the impact of less potent CYPi including drugs used to treat VMS remains largely unknown.</p><p><strong>Methods: </strong>We performed a prospective trial to evaluate the impact of gabapentin or non-potent CYPi (venlafaxine citalopram) on plasma concentrations of tamoxifen and its metabolites (Z-endoxifen, N-desmethyl-tamoxifen (NDMT) and 4-hydroxy-tamoxifen (4HT).</p><p><strong>Results: </strong>Patients enrolled were intermediate to extensive metabolizers by CYP2D6 genotyping. While tamoxifen and NDMT plasma concentrations were not significantly altered, the percent decrease in plasma Z-endoxifen concentration was statistically significant with the addition of venlafaxine (n = 22) or citalopram (n = 18) (median - 14.7 and - 14.4%, respectively) but not with gabapentin (n = 14) (median - 2.3%). A reduction in Z-endoxifen concentrations below the 5.9 ng/ml threshold associated with tamoxifen efficacy was observed in 12% of patients.</p><p><strong>Conclusion: </strong>The addition of venlafaxine and citalopram but not gabapentin during tamoxifen treatment decreases plasma Z-endoxifen concentrations. SSRIs/SNRIs affecting tamoxifen biotransformation pathways, but with less potent CYPi potential, should be used cautiously in tamoxifen-treated patients and non-CYP inhibiting medications considered when possible.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"261-270"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The regulation mechanism of perceived stress on cognitive function of patients with breast cancer undergoing chemotherapy: a multiple mediation analysis.","authors":"Xiaotong Ding, Qing Wang, Houming Kan, Fang Zhao, Mingyue Zhu, Hongli Chen, Enfeng Fu, Zheng Li","doi":"10.1007/s10549-025-07641-6","DOIUrl":"10.1007/s10549-025-07641-6","url":null,"abstract":"<p><strong>Aim: </strong>Cancer-related cognitive impairment (CRCI) is one of the severe side effects affecting the quality of life of breast cancer (BC) patients. However, the mechanisms underlying CRCI are still unclear. The study aimed to examine the multiple mediating roles of resilience, social support, cortisol, and neutrophil-lymphocyte ratio (NLR) in the relationship between perceived stress and cognitive function.</p><p><strong>Design: </strong>The study was a descriptive, cross-sectional study.</p><p><strong>Methods: </strong>The study investigated 450 BC patients with chemotherapy in China. Convenience sampling was conducted from February to August 2023. The study used the Perceived Stress Scale, the Connor-Davidson Resilience Scale, the Social Support Rating Scale, the Functional Assessment of Cancer Therapy-Cognitive Function, the Montreal Cognitive Assessment, salivary cortisol, and NLR. SPSS 25.0 and AMOS 26.0 conducted bivariate correlations and multiple mediation analysis.</p><p><strong>Results: </strong>The correlations of magnitude variables ranged from no correlation to moderate level (r = - 0.002 to - 0.617). The multiple mediation path demonstrated that resilience and morning cortisol levels mediated the relationship between perceived stress and cognitive function, with a 95% confidence interval (CI) not including 0 for the direct, indirect, and total effects.</p><p><strong>Conclusions: </strong>The study confirmed that when BC patients endure physical and psychological stress during diagnosis and treatment, individuals' resilience can buffer the stress on cognitive function. Morning salivary cortisol levels, as the product and indicator of the hypothalamic-pituitary-adrenal (HPA) axis function, may play a significant role in the effect of perceived stress on cognitive function while incapable of finding NLR as the marker of individuals' immune inflammatory response and social support play a role in this relationship. The study, based on a stress perspective, explored the regulatory mechanisms by which perceived stress affects cognitive function in patients undergoing chemotherapy for breast cancer, providing intervenable targets for subsequent improvement of patients' cognitive function.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"245-259"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment patterns and clinical outcomes in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer treated with chemotherapy: a large-scale data analysis using the Japanese claims database.","authors":"Takayuki Kimura, Tomoko Takami, Yi Piao, Meng Wang, Shigehira Saji","doi":"10.1007/s10549-025-07640-7","DOIUrl":"10.1007/s10549-025-07640-7","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to evaluate treatment patterns and clinical outcomes in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) initiating at least one chemotherapy for metastatic disease in real-world settings in Japan.</p><p><strong>Methods: </strong>In this observational retrospective cohort study, data of 2697 patients with HR+/HER2- mBC from a Japanese medical claims database who initiated the first chemotherapy in metastatic setting between January 1, 2017, and March 31, 2022, were analyzed. The study assessed treatment patterns, time to next treatment or death (TTNTD), time to treatment discontinuation, medical costs, and adverse events of interest for those receiving first-, second-, and third-line chemotherapies for mBC.</p><p><strong>Results: </strong>The most common regimens were S-1 (20.1%), eribulin (12.2%), and paclitaxel + bevacizumab (6.9%) for each line of therapy, respectively. The TTNTD decreased as treatment advanced, with medians of 8.2, 7.3, and 6.0 months for each line. Monthly medical costs were 277.1, 340.9, and 378.4 thousand yen for each line of therapy, respectively. Nausea/vomiting and neutropenia/leukopenia occurred in 62.6% and 20.5% of patients, respectively.</p><p><strong>Conclusion: </strong>This study highlights current chemotherapy practices for HR+/HER2- mBC in Japan, where treatment patterns largely align with clinical guidelines but vary according to patient characteristics. Notably, the TTNTD shortens with successive treatments, and medical costs increase, intensifying the financial burden on patients. These findings indicate unmet needs for improved treatment options that enhance outcomes and reduce patient burden in advanced therapy lines.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"233-244"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143466533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer.","authors":"Nan Chen, Margarite Matossian, Poornima Saha, Murtuza Rampurwala, Salaija Kamaraju, Olwen Hahn, Frederick M Howard, Gini F Fleming, Jincong Q Freeman, Theodore Karrison, Suzanne Conzen, Rita Nanda, Erica M Stringer-Reasor","doi":"10.1007/s10549-025-07626-5","DOIUrl":"10.1007/s10549-025-07626-5","url":null,"abstract":"<p><strong>Purpose: </strong>Glucocorticoid receptor (GR) activity may mediate chemoresistance in advanced triple-negative breast cancer (TNBC). Preclinical studies demonstrate that GR antagonism can augment the effect of taxanes in TNBC models. We hypothesized that pretreatment with mifepristone, a potent GR antagonist, would enhance nab-paclitaxel efficacy in advanced TNBC.</p><p><strong>Methods: </strong>This trial was terminated early due to poor accrual. 29 of 64 planned patients were enrolled. Patients were randomized to receive nab-paclitaxel with or without mifepristone; oral mifepristone 300 mg was administered the day prior and day of each dose of nab-paclitaxel. The primary endpoint was progression-free survival (PFS); secondary/exploratory endpoints included response rate and correlation of response with GR expression.</p><p><strong>Results: </strong>The addition of mifepristone to nab-paclitaxel did not improve PFS (3.0 m vs 3.0 m, p = 0.687) or overall response rate (23% vs 31.5%) compared to nab-paclitaxel alone. There was a trend towards improved overall survival in the combination group, primarily driven by one long-term responder. Increased rates of grade 3 neutropenia (46% vs 7%) and febrile neutropenia were observed in the combination arm, while other toxicities were similar in both groups. Increased GR expression was not correlated with clinical response in the combination arm.</p><p><strong>Conclusions: </strong>While there were responders to the combination, the study was underpowered to meet the primary endpoint. Higher rates of neutropenia were observed in the combination, but overall it was well tolerated. Preclinical data in TNBC and clinical data in other malignancies support further investigation of GR modulators. Future studies should incorporate biomarkers to select patients who benefit from GR inhibition.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"111-119"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11952973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preferences of patients with high-risk HR + /HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany.","authors":"Achim Wöckel, Tjoung-Won Park-Simon, Agnieszka Korfel, Kirsten Raab, Hans Tesch","doi":"10.1007/s10549-025-07622-9","DOIUrl":"10.1007/s10549-025-07622-9","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to identify preferences of patients with high-risk hormone receptor positive/human epidermal growth factor receptor 2 negative (HR + /HER2-) early breast cancer (EBC) related to adjuvant endocrine therapy (ET) using the Adaptive Choice-Based Conjoint (ACBC) method.</p><p><strong>Methods: </strong>A stepwise multimodal study was conducted in Germany between October 2021 and March 2022 consisting of desk research, qualitative interviews, and quantitative online surveys. Included patients had a high risk of recurrence at the time of their HR + /HER2- EBC diagnosis, completed primary therapy (surgery ± radiation + (neo)adjuvant chemotherapy), and were prescribed or undertaking adjuvant ET. In the desk research phase, online resources, patient material, and existing studies were reviewed. In the qualitative phase, interviews were conducted with 6 gynaecologists, 6 oncologists, 20 patients, and 5 caretakers. In the quantitative phase, 85 patients completed the ACBC analysis survey.</p><p><strong>Results: </strong>Included patients were aged 49.4 years (mean) among which 69.4% were still working. In the ACBC absolute rating, diarrhoea, arthralgia, and nausea were least relevant attributes to patients. Relative assessment of ET attributes against each other revealed that achieving the ET goal, namely the reduction of risk of tumour recurrence, had the highest relevance, while avoiding side effects and maintaining quality of life were less relevant. Overall, 35% have considered taking a break or discontinuing adjuvant ET due to side effects.</p><p><strong>Conclusion: </strong>Reduction of tumour recurrence was the attribute of highest relative importance for patients with high-risk HR + /HER2- EBC followed by side effect avoidance and quality-of-life maintenance, reflecting their importance in treatment decisions.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":"59-69"},"PeriodicalIF":3.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11953198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143456920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}